TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16608934

Group type: EXPERIMENTAL
Intervention: RMET by paced tube breathing
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham training (control)
Number of subjects: 36
Study: 14552510

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT), including both noncomputerized and computer‐assisted interventions, with and without strategy coaching.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental adaptation intervention.
Number of subjects: 0
Study: 11472786

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 9572337

Group type: EXPERIMENTAL
Intervention: Aortic perfusion only (APO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional combined aortic and portal perfusion (APP)
Number of subjects: 40
Study: 8060544

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg, four times daily)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 3051873

Group type: EXPERIMENTAL
Intervention: 20 ml 1% mepivacaine with epinephrine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 20 ml 1% mepivacaine without epinephrine
Number of subjects: 151

Group type: COMPARATOR
Intervention: 20 ml 1% mepivacaine with and without epinephrine
Number of subjects: 151
Study: 30156130

Group type: EXPERIMENTAL
Intervention: Herbal compress treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study: 26503631

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 25460341

Group type: EXPERIMENTAL
Intervention: Modified Cawthorne & Cooksey protocol (experimental group, n=42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cawthorne & Cooksey protocol (control group, n=40)
Number of subjects: 82
Study: 23070875

Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion program (8-week workshop)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 25
Study: 21479583

Group type: EXPERIMENTAL
Intervention: Complete resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCNU wafer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: <90% resection with BCNU wafer
Number of subjects: 0

Group type: COMPARATOR
Intervention: <90% resection with placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study: 18762532

Group type: EXPERIMENTAL
Intervention: Helmet legislation introduced in October 1995 for bicyclists <18 years of age
Number of subjects: 362
Study: 16204325

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg b.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine (20 mg mane)
Number of subjects: 0
Study: 12669760

Group type: EXPERIMENTAL
Intervention: Visual masking by object substitution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative hypothesis regarding early-stage visual processes
Number of subjects: 0
Study: 11112113

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg twice daily, FP 500 microg twice daily, FP 1,000 microg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg twice daily, BUD 800 microg twice daily, BUD 1,600 microg twice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 66
Study: 9190973

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (HRT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 1539817

Group type: EXPERIMENTAL
Intervention: 1.25% mepivacaine with bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.25% mepivacaine without bicarbonate (placebo)
Number of subjects: 0
Study: 30282450

Group type: EXPERIMENTAL
Intervention: 8th edition AJCC staging system
Number of subjects: 1633

Group type: COMPARATOR
Intervention: 7th edition AJCC staging system
Number of subjects: 1633
Study: 29685740

Group type: EXPERIMENTAL
Intervention: Digital group (Verion®, Alcon)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ink-marking group (Pendular marker, AMO)
Number of subjects: 30
Study: 26108524

Group type: EXPERIMENTAL
Intervention: Ear-acupoint pressing combined with Ear Apex (HX6,7) bloodletting
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vitamins C and E with 0.025% tretinoin cream
Number of subjects: 180

Group type: COMPARATOR
Intervention: Urea-cream (placebo)
Number of subjects: 180
Study: 25014687

Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg, once every 28 days for 96 weeks)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 204
Study: 23060037

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg daily)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Selenium (200 μg daily as selenized yeast)
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1824
Study: 21252608

Group type: EXPERIMENTAL
Intervention: Postoperative autotransfusion in knee arthroplasty
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative autotransfusion in hip arthroplasty
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group in knee arthroplasty
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group in hip arthroplasty
Number of subjects: 74
Study: 18040528

Group type: EXPERIMENTAL
Intervention: 30 ml elderberry extract (278 mg total anthocyanins)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 ml elderberry extract (1852 mg total anthocyanins)
Number of subjects: 6
Study: 16199360

Group type: EXPERIMENTAL
Intervention: Large class Integrated Learning Activity (ILA)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Traditional small group facilitated PBL sessions
Number of subjects: 246
Study: 12380791

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg orally once daily for 3 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional therapy (cefazolin plus gentamicin/cephalexin) for 3 to 4 weeks
Number of subjects: 31
Study: 10428221

Group type: EXPERIMENTAL
Intervention: Charnley total hip arthroplasty
Number of subjects: 410

Group type: COMPARATOR
Intervention: Spectron total hip arthroplasty
Number of subjects: 410
Study: 7593727

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 712
Study: 2290723

Group type: EXPERIMENTAL
Intervention: TAC I (0.5% tetracaine, 1:2000 Adrenalin, 11.8% cocaine)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TAC II (1.0% tetracaine, 1:4000 Adrenalin, 7.0% cocaine)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TAC III (1.0% tetracaine, 1:4000 Adrenalin, 4.0% cocaine)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: TAC (all formulations)
Number of subjects: 250
Study: 6937648

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30099692

Group type: EXPERIMENTAL
Intervention: Risk information presented as icon arrays
Number of subjects: 19

Group type: COMPARATOR
Intervention: Risk information presented as percentages
Number of subjects: 19
Study: 28710178

Group type: EXPERIMENTAL
Intervention: Lovaza (1.86 g of EPA and 1.5 g of DHA daily)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (no Lovaza)
Number of subjects: 262
Study: 26051571

Group type: EXPERIMENTAL
Intervention: Ren Shen Yang Rong Tang (R-S-Y-R-T)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 59
Study: 23977977

Group type: EXPERIMENTAL
Intervention: Framing therapeutic benefits as improvements in landmark survival
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Framing therapeutic benefits as improvements in median survival
Number of subjects: 2040
Study: 20951103

Group type: COMPARATOR
Intervention: Pro Children intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schoolgruiten intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study: 19248859

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 182

Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 182
Study: 17365759

Group type: EXPERIMENTAL
Intervention: Assisted self-help condition (manual, targeted video, two support phone calls)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Manual-only condition
Number of subjects: 1069
Study: 15289213

Group type: EXPERIMENTAL
Intervention: Sildenafil, 50 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11450766

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with verteporfin
Number of subjects: 0
Study: 9389781

Group type: EXPERIMENTAL
Intervention: 1 g (1 mg oestradiol) transdermal oestradiol gel continuously combined with 10 mg medroxyprogesterone acetate orally 12 days either monthly or every third month
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study: 7701266

Group type: EXPERIMENTAL
Intervention: TPN + somatostatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: TPN alone
Number of subjects: 63
Study: 2437753

Group type: EXPERIMENTAL
Intervention: Atracurium infusion (0.5 mg X kg‐1 bolus followed by 0.29‐0.44 mg X kg‐1 X h‐1 maintenance infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium infusion
Number of subjects: 0
Study: 31246120

Group type: EXPERIMENTAL
Intervention: Heliox (30% oxygen and 70% helium)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nitrogen (30% oxygen and 70% nitrogen)
Number of subjects: 6
Study: 28893921

Group type: EXPERIMENTAL
Intervention: Dietary potassium restriction with oral sodium polystyrene sulfonate if needed
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dietary advice regarding general nutrition (Control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dietary potassium restriction
Number of subjects: 47
Study: 25851691

Group type: COMPARATOR
Intervention: Selexipag alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selexipag with lopinavir/ritonavir (400/100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Selexipag alone or with lopinavir/ritonavir
Number of subjects: 20
Study: 23504631

Group type: EXPERIMENTAL
Intervention: Anisodamine treatment group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 50
Study: 21392640

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel and placebo)
Number of subjects: 499
Study: 19170145

Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (SHR‐5) pills
Number of subjects: 30

Group type: COMPARATOR
Intervention: ADAPT‐232 supplements
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 30
Study: 16579328

Group type: EXPERIMENTAL
Intervention: Nurse care coordination (NCC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: MCO services without nurse care coordination
Number of subjects: 85
Study: 15288704

Group type: COMPARATOR
Intervention: Regular daily activities in control participants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily activities in depressed participants
Number of subjects: 100
Study: 11743593

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times daily (n=20)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg twice daily (equivalent to 694 mg acyclovir twice daily) (n=18)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (n=6)
Number of subjects: 46
Study: 9437408

Group type: EXPERIMENTAL
Intervention: Cisapride 150 micrograms/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8297222

Group type: EXPERIMENTAL
Intervention: Urapidil (30mg twice daily, increased to 60mg three times a day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 31
Study: 3619586

Group type: EXPERIMENTAL
Intervention: Pizotifen (1.5 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 40
Study: 31315908

Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg two times a day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27159420

Group type: EXPERIMENTAL
Intervention: Step down dose of PPIs by half for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continue with the same dose of PPIs for 8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Step down dose of PPIs by half
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continue with the same dose of PPIs
Number of subjects: 100
Study: 26026502

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo capsules (6 g/day)
Number of subjects: 22
Study: 24520987

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22674457

Group type: EXPERIMENTAL
Intervention: Belimumab 1, 4, or 10 mg/kg plus standard therapy
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg (after switching from placebo)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 19752340

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with or without tamoxifen
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with tamoxifen
Number of subjects: 1154

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1154
Study: 17331828

Group type: EXPERIMENTAL
Intervention: True interval cancers
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Occult interval cancers
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: False-negative interval cancers
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Granular microcalcification
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dense background patterns
Number of subjects: 208
Study: 15249757

Group type: EXPERIMENTAL
Intervention: Ibuprofen-lysine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 11199954

Group type: EXPERIMENTAL
Intervention: Haloperidol plus extract of ginkgo biloba (EGb)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 82
Study: 10463317

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7603608

Group type: EXPERIMENTAL
Intervention: Alkaline bicarbonate water (Donata)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 2665062

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (200 mg X 3)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 226840

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Other forms of exogenous estrogen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31975493

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied for 5 consecutive days over the right swallowing motor cortex
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (TBS) applied for 5 consecutive days over the right swallowing motor cortex
Number of subjects: 42
Study: 31759295

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PP group
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PPHP group
Number of subjects: 660

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 660
Study: 28715286

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 126
Study: 26214341

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24389068

Group type: EXPERIMENTAL
Intervention: Core members of friendship groups
Number of subjects: 9500

Group type: EXPERIMENTAL
Intervention: Isolates
Number of subjects: 9500

Group type: EXPERIMENTAL
Intervention: Liaisons
Number of subjects: 9500
Study: 22568247

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Qubi Decoction (one bag/day for four weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Qubi Decoction
Number of subjects: 96

Group type: COMPARATOR
Intervention: Diacerein (50 mg Bid, Po) and Celecoxib (0.2 Qd, Po) (control group)
Number of subjects: 96
Study: 19195842

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg bid
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 59
Study: 17469006

Group type: EXPERIMENTAL
Intervention: Intravenous hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 minutes to a maximum of five doses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (20 mg in an intravenous bolus dose followed by 40 mg if not effective within 20 minutes, followed by 80 mg every 20 minutes to a maximum dose of 300 mg)
Number of subjects: 82
Study: 14751924

Group type: EXPERIMENTAL
Intervention: Intensive-timing induction therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard-timing induction therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: No hepatomegaly at diagnosis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Grades 3 and 4 acute GVHD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Grades 1 or 2 GVHD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Age younger than 10 years
Number of subjects: 150
Study: 11226111

Group type: EXPERIMENTAL
Intervention: Preincisional dextromethorphan (120 mg) IM 30 min before skin incision
Number of subjects: 60
Study: 9763820

Group type: EXPERIMENTAL
Intervention: Psychoprophylactic lessons for childbirth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication during pregnancy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medical assistance
Number of subjects: 100
Study: 7529535

Group type: EXPERIMENTAL
Intervention: G‐CSF alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: CY + etoposide + G‐CSF
Number of subjects: 19

Group type: COMPARATOR
Intervention: CY + GM‐CSF
Number of subjects: 19
Study: 2913556

Group type: EXPERIMENTAL
Intervention: Whey protein capsules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (human albumin powder) capsules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cow's milk-free diet (Nutramigen)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 24
Study: 1164007

Group type: EXPERIMENTAL
Intervention: Gentamicin with valley levels over 2 mug/ml
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gentamicin with peak levels over 10 mug/ml
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gentamicin with peaks over 10 mug/ml
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gentamicin initial doses of 2.0, 1.5, and 1.3 or less mpk
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 2 mpk
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gentamicin at 4.5 mpk daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gentamicin at 3.0 mpk daily
Number of subjects: 86
Study: 31032356

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB) via perineum with 0.25% ropivacaine plus 0.8% lidocaine (3-5ml)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Caudal Block (CB) with a dose of 0.5 ml/kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Caudal Block (CB)
Number of subjects: 104
Study: 29257010

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (20 mg/kg before incision, 10 mg/kg at 3, 6, 12, and 24 hours) + Topical TXA (1 g) without tourniquet
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tourniquet + Intravenous TXA + Topical TXA
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tourniquet only
Number of subjects: 150
Study: 26356105

Group type: EXPERIMENTAL
Intervention: Acupuncture (Group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 59
Study: 23145894

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (Group P, n=58)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (Group NP, n=31)
Number of subjects: 89
Study: 22379923

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pantoprazole (80 mg/day)
Number of subjects: 51
Study: 19938143

Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Triple therapy (tacrolimus, azathioprine, and steroids)
Number of subjects: 103
Study: 17255126

Group type: COMPARATOR
Intervention: No exposure to RAS blockades
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ACEI alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ARB alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ACEI+ARB combination
Number of subjects: 62